ライブ
FierceBiotechErasca hits ‘home run’ with cancer data as analyst suggests stock drop prompted by patient deathFierceBiotechIncyte’s JAK inhibitor scores phase 3 vitiligo wins but can’t quite shake off RinvoqFierceBiotechAbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisitionFierceBiotechProtagonist opts for $475M in Takeda payouts instead of splitting US rusfertide profitsCellGlobal genetic interaction network of a human cell maps conserved principles and informs functional interpretation of gene co-essentiality profilesCellStabilizing MARCH7 as a ferro-guardian against ferroptosisBioPharma DiveBoehringer dual-acting obesity shot hits mark in Phase 3 trialBioWorldRead BioWorld's AACR 2026 coverageEndpoints NewsRocket's PRV goes for $180M; Oruka targets $500M offeringEndpoints NewsBeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGFEndpoints NewsIncyte claims double Phase 3 win in vitiligo, will file for approvalBioPharma DiveFDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
Revvity 2026年1月12日

Revvity, Lilly Expand Access to Federated AI Drug Discovery Models - Lab Manager

Revvity, Lilly Expand Access to Federated AI Drug Discovery Models - Lab Manager

原文
本文は利用できません。元の情報源をご確認ください。